Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Real-World Analysis of Dapagliflozin Initiation in Patients with Heart Failure and Reduced Ejection Fraction in the UK

  • By

  • Steven Coombs

  • Angela Tithecott

  • Cristina Thiebaud

  • Parminder Chaggar

  • Diane Barker

  • Prithwish Banerjee

  • Henry Oluwasefunmi Savage

  • Alastair Gray

  • Geraint Jenkins

  • Mohammad Albarjas

  • Liz Hennessy

  • Joanna De Courcy

  • Hannah Wallis

  • Thom Dewar

  • Reece Manuell

  • Sophie Barlow

  • Samuel Adamsson Eryd

  • Jil Billy Mamza

  • Tamsin Morris

  • September 8, 2026

Share

Clinical Scorecard: Real-World Analysis of Dapagliflozin Initiation in Patients with Heart Failure and Reduced Ejection Fraction in the UK

At a Glance

CategoryDetail
ConditionHeart Failure with Reduced Ejection Fraction (HFrEF)
Key MechanismsSodium-glucose cotransporter-2 inhibitor (SGLT2i) action
Target PopulationUK adults with HFrEF
Care SettingOutpatient or inpatient settings

Key Highlights

  • Mean age of participants was 69.3 years; 70.0% were male.
  • Dapagliflozin discontinuation rate was 11.7/100 patient-years, primarily due to adverse drug reactions.
  • Quality of life (QoL) scores improved from KCCQ-23 mean of 67.6 to 71.6 over 12 months.
  • Work impairment decreased from 31.2% to 16.3% at 12 months.
  • Adherence to treatment was high with MARS-5 scores averaging at least 23.1.

Guideline-Based Recommendations

Diagnosis

  • Heart failure is diagnosed based on structural and/or functional cardiac abnormalities.

Management

  • Initiate and optimize all four therapeutic pillars: RAASi, beta blockers, MRA, and SGLT2i.

Monitoring & Follow-up

  • Monitor patient-reported outcomes and treatment adherence at regular intervals.

Risks

  • Adverse drug reactions are a significant reason for discontinuation of dapagliflozin.

Patient & Prescribing Data

Patients with HFrEF who are naïve to SGLT2i.

Real-world data indicates a need for optimization of therapy as many patients lacked one or more treatment pillars.

Clinical Best Practices

  • Ensure comprehensive assessment of patient characteristics before initiating dapagliflozin.
  • Regularly evaluate QoL and adherence through validated patient-reported outcome measures.

Related Resources & Content

Original Source(s)

Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom

  • by Steven Coombs, Angela Tithecott, Cristina Thiebaud, Parminder Chaggar, Diane Barker, Prithwish Banerjee, Henry Oluwasefunmi Savage, Alastair Gray, Geraint Jenkins, Mohammad Albarjas, Liz Hennessy, Joanna De Courcy, Hannah Wallis, Thom Dewar, Reece Manuell, Sophie Barlow, Samuel Adamsson Eryd, Jil Billy Mamza, Tamsin Morris

  • September 8, 2026

Related Content

When Heart Failure Treatment Isn’t Enough: Signs It’s Time to Refer for Advanced Heart Failure Care

Advanced heart failure does not always present as a single defining event. Referring physicians may instead notice a pattern of worsening symptoms, recurrent hospitalizations or increasing difficulty maintaining a patient’s clinical stability.

  • by

  • August 28, 2026

  • 6 min
Validation of femoral pressure-derived assessment of effective arterial elastance in porcine ischemic cardiogenic shock

Myocardial function recovery in peripartum cardiomyopathy: the role of global longitudinal strain and myocardial work